Detalles de la búsqueda
1.
The Cellular Characterization of SARS-CoV-2 Spike Protein in Virus-Infected Cells Using the Receptor Binding Domain Binding Specific Human Monoclonal Antibodies.
J Virol;
96(13): e0045522, 2022 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35727030
2.
Neutralization escape of emerging subvariants XBB.1.5/1.9.1 and XBB.2.3 from current therapeutic monoclonal antibodies.
J Med Virol;
95(9): e29074, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37665160
3.
IDentif.AI-Omicron: Harnessing an AI-Derived and Disease-Agnostic Platform to Pinpoint Combinatorial Therapies for Clinically Actionable Anti-SARS-CoV-2 Intervention.
ACS Nano;
16(9): 15141-15154, 2022 09 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35977379
4.
First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.
Infect Dis Ther;
11(5): 1999-2015, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36058990
5.
The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens.
NPJ Digit Med;
5(1): 83, 2022 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35773329
6.
IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development.
Bioeng Transl Med;
6(1): e10196, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33532594
7.
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
PLoS One;
16(6): e0253487, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34161386
8.
Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.
PLoS One;
8(10): e76571, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24204639
Resultados
1 -
8
de 8
1
Próxima >
>>